Literature DB >> 13679383

HBsAg/HLA-A2 transgenic mice: a model for T cell tolerance to hepatitis B surface antigen in chronic hepatitis B virus infection.

D Loirat1, M Mancini-Bourgine, J-P Abastado, M-L Michel.   

Abstract

A humanized murine model was developed to study T cell tolerance to the hepatitis B surface antigen (HBsAg) that is present in sera of hepatitis B virus chronic carriers. The HBsAg/HLA-A2 double-transgenic mice express a chimeric HLA-A2 MHC class I molecule and a high amount of the HBsAg in the liver that is secreted and present in sera during the animal's lifetime. In these mice, injection of plasmid DNA encoding HBsAg induced a high frequency of CD8(+) T cells secreting IFN-gamma in the periphery, with in vitro cytolytic activity and specificity for two dominant HBs-specific HLA-A2-restricted epitopes. Nevertheless, the DNA-based immunization elicited neither T(h)1 nor T(h)2 CD4(+) T cell responses. Despite a high concentration of HBsAg in sera, these mice developed an immunocompetent CD8(+) T cell repertoire towards the viral self-antigen, whereas the CD4(+) T cell repertoire was tolerized. In the absence of a CD4(+) T cell response, the IFN-gamma-secreting CD8(+) T cells primed by DNA-based immunization were unable to exert their antiviral functions in vivo on liver cells expressing the transgene product. However, when pro-inflammatory stimuli were given before or after DNA-based immunization, the HBsAg was cleared from the serum. This effect was antibody dependent and associated with the detection of an HBs-specific T(h)1 CD4(+) T cell response in the periphery. This model provides evidence that HBsAg displayed a strong tolerogenic effect on the CD4(+) T cell compartment that is associated with a defect in CD8(+) T cell effector functions in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13679383     DOI: 10.1093/intimm/dxg117

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  12 in total

1.  Use of pre-S protein-containing hepatitis B virus surface antigens and a powerful adjuvant to develop an immune therapy for chronic hepatitis B virus infection.

Authors:  Jung Sun Yum; Byung Cheol Ahn; Hyun Jin Jo; Dong Yeon Kim; Ki Hyun Kim; Hyo Sun Kim; Young Chul Sung; Jaeseung Yoon; John Morrey; Hong Mo Moon
Journal:  Clin Vaccine Immunol       Date:  2011-12-07

2.  A mouse model for HBV immunotolerance and immunotherapy.

Authors:  Dan Yang; Longchao Liu; Danming Zhu; Hua Peng; Lishan Su; Yang-Xin Fu; Liguo Zhang
Journal:  Cell Mol Immunol       Date:  2013-09-30       Impact factor: 11.530

3.  Impact of the Immunogen Nature on the Immune Response against the Major HBV Antigens in an HBsAg and HLA-humanized Transgenic Mouse Model.

Authors:  M Mancini-Bourgine; G Guillen; M L Michel; J C Aguilar
Journal:  Euroasian J Hepatogastroenterol       Date:  2014-01-22

4.  An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection.

Authors:  Li-Rung Huang; Hui-Lin Wu; Pei-Jer Chen; Ding-Shinn Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-09       Impact factor: 11.205

5.  No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.

Authors:  Megan Crane; Sunee Sirivichayakul; J Judy Chang; Anchalee Avihingsanon; Sasiwimol Ubolyam; Supranee Buranapraditkun; Pattarawat Thantiworasit; Fiona Wightman; Stephen Locarnini; Gail Matthews; Gregory J Dore; Kiat Ruxrungtham; Sharon R Lewin
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

6.  Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus.

Authors:  Marjoleine L Op den Brouw; Rekha S Binda; Mark H van Roosmalen; Ulrike Protzer; Harry L A Janssen; Renate G van der Molen; Andrea M Woltman
Journal:  Immunology       Date:  2008-06-28       Impact factor: 7.397

7.  Study of human B7 homolog 1 expression in patients with hepatitis B virus infection.

Authors:  Wen-Jin Zhang; Hai-Yang Xie; Xin Duan; Yun-Le Wan; Chuan-Hui Peng; Shao-Hua Shi; Rong Su; Zhang-Hui Zheng; Le-Lin Pan; Lin Zhou; Shu-Sen Zheng
Journal:  World J Gastroenterol       Date:  2012-07-28       Impact factor: 5.742

8.  Effects of costimulation on intrahepatic immunopathogenesis in patients with chronic HBV infection.

Authors:  Bei Zhong; Mao Ping Huang; Guo Qing Yin; Xiang Gao
Journal:  Inflamm Res       Date:  2013-12-14       Impact factor: 4.575

9.  Intrahepatic Toll-Like Receptor 3 in Chronic HBV Infection Subjects: Asymptomatic Carriers, Active Chronic Hepatitis, Cirrhosis, and Hepatocellular Carcinoma.

Authors:  Jia Wen Yin; Mao Ping Huang; Bei Zhong
Journal:  Hepat Mon       Date:  2016-05-23       Impact factor: 0.660

Review 10.  Technical Improvement and Application of Hydrodynamic Gene Delivery in Study of Liver Diseases.

Authors:  Mei Huang; Rui Sun; Qiang Huang; Zhigang Tian
Journal:  Front Pharmacol       Date:  2017-08-30       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.